Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis

被引：0
|
作者：
Bresse, Xavier [1 ]
Annemans, Lieven [2 ]
Preaud, Emmanuelle [1 ]
Bloch, Karine [1 ]
Duru, Gerard [3 ]
Gauthier, Aline [4 ]
机构：
[1] Sanofi Pasteur MSD, F-69367 Lyon 07, France
[2] Univ Ghent, B-9000 Ghent, Belgium
[3] CYKLAD Grp, F-69130 Rillieux La Pape, France
[4] Amaris, London NW1 8NZ, England
来源：
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2013年 / 13卷 / 03期
关键词：
cost-effectiveness; herpes zoster; herpes zoster vaccine; postherpetic neuralgia; vaccination; QUALITY-OF-LIFE; ECONOMIC-EVALUATION; HEALTH-CARE; PAIN; PREVENTION; SHINGLES; BURDEN; VARICELLA; IMPACT; EPIDEMIOLOGY;
D O I：
10.1586/ERP.13.19
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
This study assesses the cost-effectiveness of vaccination against herpes zoster (HZ) and postherpetic neuralgia in France, using a published Markov model. The cost-effectiveness of vaccinating individuals aged from 65 years or between 70 and 79 years was evaluated over their lifetime, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol five-dimension questionnaire) utilities from the literature. HZ vaccination was highly cost effective in both populations. Incremental cost-effective ratios were estimated between (sic)9513 and 12,304 per quality-adjusted life year gained, corresponding to (sic)2240-2651 per HZ case avoided and (sic)3539-4395 per postherpetic neuralgia case avoided. In addition to epidemiological and clinical evidence, economic evidence also supports the implementation of HZ vaccination in France.
引用
收藏
页码：393 / 406
页数：14
相关论文
共 50 条
  • [1] Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review
    Kawai, Kosuke
    Preaud, Emmanuelle
    Baron-Papillon, Florence
    Largeron, Nathalie
    Acosta, Camilo J.
    [J]. VACCINE, 2014, 32 (15) : 1645 - 1653
  • [2] COST-EFFECTIVENESS OF VACCINATION AGAINST HERPES ZOSTER AND POSTHERPETIC NEURALGIA: A CRITICAL REVIEW
    Kawai, K.
    Preaud, E.
    Baron-Papillon, F.
    Acosta, C. J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A334 - A334
  • [3] VACCINATION AGAINST HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN FRANCE: A COST-EFFECTIVENESS ANALYSIS
    Bresse, X.
    Annemans, L.
    Bloch, K.
    Duru, G.
    Gauthier, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A396 - A396
  • [4] Vaccination against herpes zoster and postherpetic neuralgia
    Oxman, Michael N.
    Levin, Myron J.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2008, 197 : S228 - S236
  • [5] Cost-effectiveness of herpes zoster vaccine: Flawed assumptions regarding efficacy against postherpetic neuralgia
    Brisson, Marc
    Pellissier, James M.
    Levin, Myron J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 45 (11) : 1527 - 1529
  • [6] Cost-effectiveness of vaccination against herpes zoster
    de Boer, Pieter T.
    Wilschut, Jan C.
    Postma, Maarten J.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 2048 - 2061
  • [7] Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    Hornberger, John
    Robertus, Katherine
    [J]. ANNALS OF INTERNAL MEDICINE, 2006, 145 (05) : 317 - 325
  • [8] Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    Rothberg, Michael B.
    Virapongse, Anunta
    Smith, Kenneth J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (10) : 1280 - 1288
  • [9] The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia
    Brisson, Marc
    Pellissier, James M.
    Camden, Stephanie
    Quach, Caroline
    De Wals, Philippe
    [J]. HUMAN VACCINES, 2008, 4 (03): : 238 - 245
  • [10] COST EFFECTIVENESS ANALYSIS OF A VACCINE TO PREVENT HERPES ZOSTER AND POSTHERPETIC NEURALGIA IN ITALY
    Coretti, S.
    Ruggeri, M.
    Codella, P.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A511 - A511
12345